Impact of the application of the JNC 8 and KDIGO-2013 guidelines on hypertension and lipid control in a nephrology outpatient clinic

Statin use before and after the KDIGO Lipids in chronic kidney disease guideline: A population‐based interrupted time series analysis

“…Further, the Danish health‐care registers are renowned for their high coverage, validity and quality. 8 , 11 Previous studies have investigated nephrology outpatients, who may not be representative of the entire KDIGO guideline target population, 6 , 7 as less than 10% of patients with CKD are seen by a nephrologist. 12 Our cohort includes both CKD patients who are followed by nephrologists and non‐followed patients.…”

“…Since 2013, the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease has recommended statin and/or ezetimibe treatment to all who are 50 years or older, with an estimated Glomerular Filtration Rate (eGFR) below 60 ml/min/1.73 m 2 , except for individuals receiving dialysis treatment 5 . There is little evidence on the adherence to the 2013 KDIGO Guidelines for lipid management 6,7 . Therefore, we aimed to estimate the impact of the KDIGO guideline publication on the clinical implementation of statin treatment in an unselected population of patients with an eGFR below 60 ml/min/1.73 m 2 .…”

“… 5 There is little evidence on the adherence to the 2013 KDIGO Guidelines for lipid management. 6 , 7 Therefore, we aimed to estimate the impact of the KDIGO guideline publication on the clinical implementation of statin treatment in an unselected population of patients with an eGFR below 60 ml/min/1.73 m 2 .…”